Business Account Executive, Rare: Arizona
Alnylam Pharmaceuticals | |
United States, Massachusetts, Cambridge | |
675 West Kendall Street (Show on map) | |
Dec 03, 2024 | |
This role is considered Virtual. Overview We are looking for an experienced and talented Business Account Executive (BAE) to commercially represent GIVLAARI and OXLUMO in the United States and have a significant impact on the lives of AHP patients. AHP's represent a sub-group of Porphyrias, characterized by the occurrence of neuro-visceral attacks with or without cutaneous manifestations. AHP's include four disorders: acute intermittent porphyria (the most common), variegate porphyria, hereditary coproporphyria, and a genetic deficit of delta-aminolaevulinic acid dehydratase. PH1 is a rare, life-threatening disease that can cause serious damage to kidneys and progressively to other organs. PH1 is a little-known condition and patients often spend years undiagnosed and misdiagnosed. The BAE will be principally responsible for driving physician and patient identification, disease awareness, overall market development, and brand awareness within their ascribed territory. The BAE will be responsible for achieving territory targets and other business objectives through account and customer strategies, while also partnering & collaborating very closely with internal and external stakeholders to effectively manage all aspects of the regional business. The achievement of targets will be based in Alnylam's values: our commitment to people, sense of urgency, passion for excellence, innovation & discovery, and open culture as well as our unwavering commitment to integrity. The BAE will report to the Regional Business Director (RBD) for their respective region. Key Responsibilities
Qualifications
About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. > |